Filter
260
Text search:
second
booster
Featured
Recommendations
22
New Publications
60
Language
Document type
No document type
127
Guidelines
59
Studies & Reports
26
Fact sheets
14
Manuals
13
Strategic & Response Plan
10
Training Material
4
Brochures
3
Situation Updates
3
Resource Platforms
1
Countries / Regions
India
16
Global
13
South Africa
7
Philippines
6
Congo, Democratic Republic of
5
Zambia
5
Nigeria
4
Tanzania
4
Namibia
4
Western and Central Europe
4
Africa
4
Ghana
3
Kenya
3
Ukraine
3
Lesotho
3
Latin America and the Carribbean
3
Liberia
2
Uganda
2
Zimbabwe
2
Nepal
2
Rwanda
2
Mozambique
2
Brazil
2
East and Southern Africa
2
Sierra Leone
1
Senegal
1
Germany
1
Indonesia
1
Benin
1
Argentina
1
Colombia
1
Botswana
1
Myanmar / Burma
1
South–East Asia Region
1
Western Pacific Region
1
Eastern Europe and Central Asia
1
Fiji
1
Venezuela
1
Eastern Europe
1
Moldova
1
Authors & Publishers
Publication Years
Category
Countries
86
Clinical Guidelines
47
Women & Child Health
19
Public Health
15
Key Resources
4
Capacity Building
3
Pharmacy & Technologies
1
Toolboxes
COVID-19
51
HIV
17
Mental Health
15
TB
11
Polio
9
Pharmacy
7
Conflict
6
Caregiver
6
Refugee
5
Planetary Health
5
Ebola
4
Rapid Response
4
NTDs
4
NCDs
3
Disability
2
Cholera
2
Natural Hazards
2
AMR
2
Health Financing Toolbox
2
Specific Hazards
1
Global Health Education
1
Supplement to the 2016 consolidated Guidelines on the use of antiretroviral drugs for Treating and Preventing HIV infection
HIV Treatment
About one fourth of the world’s population is estimated to have been infected with the tuberculosis (TB) bacilli, and about 5–10% of those infected develop TB disease in their lifetime. The risk for TB disease after infection depends on several factors, the most important being the person’s im
...
July 2019
Policy brief
HIV Treatment
These WHO interim recommendations on the use of the Astra Zeneca – Oxford University AZD1222 vaccine against Covid-19 were developed on the basis of advice issued by the Strategic Advisory Group of Experts on Immunization (SAGE) and the evidence summary included in the background document referenc
...
This document aims to provide interim guidance for microbiology and virology experts, other laboratory professionals, laboratory managers, infectious disease programme managers, public health professionals and other stakeholders that provide primary, confirmatory or advanced testing for SARS-CoV-2,
...
Declarations of interests were collected from all external contributors and assessed for any conflicts of interest. Summaries of the reported interests can be found on the SAGE meeting website and SAGE Covid-19 Working Group webpage. This guidance should be considered along with the broader COVID-
...
27 September 2022
These WHO interim recommendations for use of the Novavax NVX-CoV2373 vaccine were developed on the basis of advice issued by the Strategic Advisory Group of Experts on Immunization (SAGE) and the evidence summary included in the background document and annexes referenced below.
nterim guidance, first issued 25 January 2021, updated 15 June 2021, updated 19 November 2021, updated 23 February 2022, updated 18 August 2022
These WHO interim recommendations on the use of the Pfizer – BioNTech BNT162b2 vaccine against Covid-19 were developed on the basis of advice issued by the Strategic Advisory Group of Experts on Immunization (SAGE) and the evidence summary included in the background document referenced below.
fir
...
Interim recommendations for use of the inactivated COVID-19 vaccine, CoronaVac, developed by Sinovac
These WHO interim recommendations for use of the Sinovac-CoronaVac were developed on the basis of advice issued by the Strategic Advisory Group of Experts on Immunization (SAGE) and the evidence summary included in the background document and annexes referenced below.
This document has been updat
...
Weekly epidemiological record/ Relevé épidémiologique hebdomadaire 4 AUGUST 2017, 92th YEAR / 4 AOÛT 2017, 417-436
These WHO interim recommendations for use of the COVID-19 vaccine BIBP produced by Sinopharm were developed on the basis of advice issued by the Strategic Advisory Group of Experts on Immunization (SAGE) and the evidence summary included in the background document and annexes referenced below.
Th
...
first issued 18 August 2022
